CHEK1 and cancer: This is consistent withCRISPR-based sensitivity profiles across a broad panel of cancer celllines (downloaded from depmap.org), which show that PALB2 deletion imposes fewer deleterious effectsthan other high-value oncology targets, such as ATR or CHEK1 (seedata from depmap.org in the Supporting InformationSection S7).